Track Collegium Pharmaceutical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Collegium Pharmaceutical, Inc. COLL · Stock Open Collegium Pharmaceutical, Inc. in new tab

25.32 USD
P/E
22.76
EPS
1.09
P/B
2.60
ROE
13.36
Beta
0.73
Target Price
44.88 USD
Collegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc.

🧾 Earnings Recap – Q3 2026

Collegium shares rose 6.3% after earnings as ADHD growth—particularly record Jornay PM revenue—and reaffirmed 2026 guidance appear to have outweighed modest 3% year-over-year growth in total revenue. The quarter’s upside was concentrated in ADHD, while the pain portfolio remained a large but steady contributor.

  • Net revenue reached a record $216.3 million, up 3% year over year, driven by ADHD growth during the back-to-school season.
  • Jornay PM revenue increased 24% to a record $59.5 million; prescriptions rose 16%, and nearly 33,000 healthcare providers prescribed it, up 19%.
  • Azstarys generated $26.5 million in its first full quarter under Collegium’s ownership; prescriptions grew nearly 2% year over year after declining in 2025.
  • The pain portfolio generated $138 million, which management said was in line with expectations and consistent with full-year 2026 guidance.
  • Management reaffirmed 2026 guidance, including $190 million–$200 million for Jornay PM and $65 million–$75 million in partial-year Azstarys revenue, and announced a $50 million accelerated share repurchase.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E22.76
EPS1.09
Book Value9.54
Price to Book2.60
Debt/Equity407.38
% Insiders1.205%
Growth
Revenue Growth0.03%
Earnings Growth-0.29%
Estimates
Forward P/E3.47
Forward EPS7.16
Target Mean Price44.88

DCF valuation

Model fair value for Collegium Pharmaceutical, Inc. (COLL)
Result
Sign in to run the valuation for COLL.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
8 analysts · consensus Strong buy · mean target 44.88 USD (low 28.00, high 60.00) · as of 12 Nov 2026
Low 28.00
Mean 44.88
High 60.00
Price 25.32
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Collegium Pharmaceutical, Inc. Logo Collegium Pharmaceutical, Inc. Analysis (COLL)

United States Health Care Official Website Stock

Is Collegium Pharmaceutical, Inc. a good investment? Collegium Pharmaceutical, Inc. (COLL) is currently trading at 25.32 USD. Market analysts have a consensus price target of 44.88 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 22.76. This valuation is generally in line with the broader market.

Earnings Schedule: Collegium Pharmaceutical, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 7.16.

Investor FAQ

Does Collegium Pharmaceutical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Collegium Pharmaceutical, Inc.?

Collegium Pharmaceutical, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 1.09.

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Exchange Ticker
NMS (United States) COLL
FRA (Germany) 354.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion